Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hematology
•
Internal Medicine
How would you manage a healthy young adult patient with nodular lymphocyte predominant Hodgkin lymphoma with steroid-responsive severe hemolytic anemia and no other symptoms?
Related Questions
How would you approach treatment with BV-CHP regimen in a patient with newly diagnosed CD30+ ALK- anaplastic large cell lymphoma at high risk for cardiotoxicity?
How do you approach patient with CLL/SLL limited to the prostate?
Do you utilize ctDNA-based MRD testing after frontline chemotherapy for DLBCL?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you approach adjusting nivo+AVD therapy for advanced Hodgkin lymphoma if a patient develops treatment limited immunotherapy toxicity?
How would you structure your monitoring for a low-risk leukemic TP53-negative mantle cell lymphoma with 5% MCL cells detected in both peripheral blood and bone marrow, mild splenomegaly, and no lymphadenopathy or B symptoms?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
